Mediraw Pharma & Nutra Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.10 M
- Revenue Growth 62.17%
- Profit Growth 158.42%
- Ebitda -8237.74%
- Net Worth 129.57%
- Total Assets 33.54%
About Mediraw Pharma & Nutra
Mediraw Pharma & Nutra Private Limited (MPNPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 August 2021 (Three years and five months 28 days old ). Its registered office is in Solan, Himachal Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.10 M.
Parveen Kumar and Anish Rana serve as directors at the Company.
Company Details
-
Location
Solan, Himachal Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24290HP2021PTC008734
-
Company No.
008734
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Aug 2021
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Himachal Pradesh
Industry
Who are the key members and board of directors at Mediraw Pharma & Nutra?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parveen Kumar
|
Additional Director | 16-Oct-2024 | Current |
|
Anish Rana
|
Additional Director | 16-Oct-2024 | Current |
Financial Performance of Mediraw Pharma & Nutra.
Mediraw Pharma & Nutra Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 62.17% increase. The company also saw a substantial improvement in profitability, with a 158.42% increase in profit. The company's net worth Soared by an impressive increase of 129.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mediraw Pharma & Nutra?
Unlock access to Mediraw Pharma & Nutra's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Medicef Pharma LimitedParveen Kumar and Anish Rana are mutual person
Charges (Loans)
₹4.10 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.41 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jul 2022 | Hdfc Bank Limited | ₹4.10 M | Open |
How Many Employees Work at Mediraw Pharma & Nutra?
Unlock and access historical data on people associated with Mediraw Pharma & Nutra, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mediraw Pharma & Nutra, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediraw Pharma & Nutra's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
